The reduction of DAT binding in the prodromal stage of PD suggests an early synaptic dysfunction and the activation of compensatory changes to delay the onset of symptoms.[34,37] Therefore, quantitative measurements of DAT binding at baseline could predict the emergence of late-disease motor fluctuations and dyskinesias.[37]. Here, SLC6A3 is linked to drug-induced dyskinesia.